B · Normal
[State Food and Drug Administration approves the marketing of Ashuxen Tablets] On October 26, the State Food and Drug Administration approved the listing of the Class 1 innovative drug Ashuxen Tablets (trade name: Shuhuabo) applied by Bayer AG through the priority review and approval process. The drug is used to reduce the risk of stroke in adult patients with ischemic stroke or high-risk transient ischemic attack (TIA), excluding patients with cardioembolic stroke. The launch of this drug provides patients with new treatment options.
Comments